Impact of Netrin-1 in the Pathophysiology of Placenta Accreta Spectrum
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
- To evaluate the immunohistochemical expression of these proteins in PAS specimens in comparison with the control placental tissues.
- To correlate their expression with the demographic parameters.
- To assess the correlation between their expression in PAS specimens.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: hanaa mohammed mohammed sayed, assistant lecturer
- Phone Number: 01016113232
- Email: hanaa.dwak@yahoo.com
Study Contact Backup
- Name: heba mahmoud iraqy, lecturer
- Phone Number: 01099073405
- Email: dr.heba20@yahoo.com
Study Locations
-
-
-
Assiut, Egypt
- Hanaa Mohammed Mohammed Sayed
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
inclusion criteria
- PAS patients who underwent hysterectomy to allow proper pathologic grading of PAS
exclusion criteria
- patients with fundal and middle anterior or posterior placenta,
- pregnancy associated with morbid conditions such as hypertension, diabetes mellitus, autoimmune disease, cardiac disease, renal disease, history of anemia, blood transfusion, other blood diseases and endocrinal disease; fetal distress or intrauterine growth retardation.
- uterine scar pregnancies were excluded
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
group A
30 placental specimens of PAS
|
no intervention applied
|
|
group B
30 placental specimens of heaithy women with normal pregnancy
|
no intervention applied
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
impact of netrin-1 in the pathophysiology of placenta accreta spectrum
Time Frame: baseline
|
|
baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- netrin-1 in placenta accreta
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.